<code id='EEA5850146'></code><style id='EEA5850146'></style>
    • <acronym id='EEA5850146'></acronym>
      <center id='EEA5850146'><center id='EEA5850146'><tfoot id='EEA5850146'></tfoot></center><abbr id='EEA5850146'><dir id='EEA5850146'><tfoot id='EEA5850146'></tfoot><noframes id='EEA5850146'>

    • <optgroup id='EEA5850146'><strike id='EEA5850146'><sup id='EEA5850146'></sup></strike><code id='EEA5850146'></code></optgroup>
        1. <b id='EEA5850146'><label id='EEA5850146'><select id='EEA5850146'><dt id='EEA5850146'><span id='EEA5850146'></span></dt></select></label></b><u id='EEA5850146'></u>
          <i id='EEA5850146'><strike id='EEA5850146'><tt id='EEA5850146'><pre id='EEA5850146'></pre></tt></strike></i>

          Home / knowledge / hotspot

          hotspot


          hotspot

          author:Wikipedia    Page View:56439
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In